EpiHeart is a young medical device company, enabling a new therapy for ischemic cardiac scars and heart failure.
EpiHeart is dedicated to improve long term survival and quality of life of the patients having Cardiac Artery Bypass Grafting (CABG). Based on intial pre-clinical and clinical results the epicardial transplantation of autologous cells during the CABG surgery reduces the scar tissue and fibrosis causing heart failures
EpiHeart is a spin-off company leveraging over 10 years of dedicated research conducted on three continents. Our home is Helsinki, Finland, where we have deep collaboration with University of Helsinki, Helsinki University Hospital "HUS" and Aalto University.
Epiheart is open for collaboration. We foresee collaboration possibilites:
Feel free to request further information on our science, clinical trial program and more.
Tel. +358 40 751 6763
Haartmaninkatu 4, building 14 (Terkko Health Hub), 00290 Helsinki, Finland